AMRN. Tengo la media en $2... Este año debería subir con las 2 victorias judiciales que la FDA debe cumplir... A ver si la puedo vender a final de año por lo menos a $3.
NVAX. Tengo la media en $6,9 y tal vez compre alguna mas para bajarla a $6,5. Multiplicar x 2,5 a fin de año estaría de lujo... veremos...
OK, zunzun, comento algo que dicho en otras ocasiones (hace mucho), sobre los posts usanos que subo de yahoo board de ciento en viento. Me conozco el 99% de lo que dicen los posters serios desde hace ya mas de un par de años. Este es de los serios pero OJO que esta diciendo que tiene info de primera mano , por eso dije lo de "entretenimiento". Cuando subo post de ciencia es lo que es, ciencia. Pero sin pruebas eso es una teoria mas. Vale, apunta al asunto partner como ya hemos insinuado tb por aqui. Pero no deja de ser lo que es.
NVAX
NVAX
Cramer ayudando??? Me da que hoy vemos verde en NVAX....
http://www.thestreet.com/mad-money/index.html
Novavax (NVAX) : "It's down so low, I like this one. Let's take a longer-term view."
Exclusive Mad Money Stock Screener
Cramer's Calls For: 01/28/2016
Company Date Segment Call Price Portfolio
Apple (AAPL) 01/28 D 5 $94.09 add
Avnet (AVT) 01/28 I 5 $38.82 add
Baxter International (BAX) 01/28 L 5 $35.70 add
Becton Dickinson (BDX) 01/28 L 2 $142.28 add
Cambrex (CBM) 01/28 L 2 $33.92 add
Celgene (CELG) 01/28 L 5 $97.21 add
Facebook (FB) 01/28 F 5 $109.11 add
General Electric (GE) 01/28 D 4 $28.21 add
Illumina (ILMN) 01/28 L 4 $154.25 add
JD.com (JD) 01/28 L 1 $25.37 add
3M (MMM) 01/28 D 4 $147.32 add
Novavax (NVAX) 01/28 L 5 $4.87 add
Opko Health (OPK) 01/28 L 4 $7.69 add
T-Mobile US (TMUS) 01/28 L 5 $38.67 add
United Technologies (UTX) 01/28 D 4 $86.45 add
NVAX
In the Lightning Round, Cramer was bullish on T-Mobile US (TMUS) , Baxter International (BAX) , Illumina (ILMN) , Novavax (NVAX) , Celgene (CELG) and Opko Health (OPK) .
Drug Companies are Leaving - The drug companies have been leaving the U.S. as the campaign rhetoric becomes louder. In late November, Dublin-based Allergan (NYSE:AGN) said it was buying Pfizer (NYSE:PFE) in a $160 billion deal, although the combined company will be known as Pfizer Plc. U.S. President Barack Obama has called this type of deal, or inversion, unpatriotic. Pfizer's Chief Executive Officer Ian Read thinks differently as he put it, "the deal would help put the company on a more competitive footing." "The fact that Pfizer is leaving our country with a tremendous loss of jobs is disgusting," Trump said back then.
Democratic Candidates' Plans - Democratic U.S. Presidential candidates have been feeling increasing pressure to develop answers for the problem of high-cost prescription drugs. In October, Hillary Clinton proposed capping out-of-pocket drug expenses at $250 a month, reducing the exclusivity period to 7 years from its current 12 years, and requiring most drug makers to spend a defined portion of their profits on research and development. The Clinton plan wouldn't allow Medicare to negotiate prices of all drugs, but is limited to biologics and high-cost drugs, in line with the Obama budget proposal released earlier last year. Her rival, Senator Bernie Sanders, a Democratic Socialist, wants people to be able to buy low-cost drugs from Canada and to allow Medicare to negotiate prices with drug companies without limits.
Two weeks ago, another Dublin-based biopharmaceutical company, Shire (NASDAQ:SHPG) said it was acquiring an Illinois company, Baxalta Inc. (NYSE:BXLT), in a $32 billion deal to create the world's largest rare-disease drugmaker.
Since September 21, when Mrs. Clinton went on a Twitter frenzy and sent out a tweet about "outrageous" price gouging by a pharmaceutical CEO, the share price of IBB has plunged over 22%. About 42.75% of the holdings in the IBB index are the five big cap biotech companies, Celgene (NASDAQ:CELG), Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN), with a combined market cap of over $438 billion.
IBB Technical Chart
http://seekingalpha.com/article/3839886-campaign-rhetoric-adds-volatility-nasdaq-biotechnology-index
GILD
Qué raro, no veo news y que yo sepa no presenta resultados hasta la semana que viene.
AMGN
Sorprendente que no suba más en pre-market (está prácticamente plana) tras los buenos resultados presentados ayer al cierre.
